Myriad Genetics, Inc. (MYGN): ANSOFF-Matrixanalyse

In der sich schnell entwickelnden Landschaft der Präzisionsmedizin steht Myriad Genetics, Inc. an der Spitze transformativer Genteststrategien. Durch die sorgfältige Erstellung einer umfassenden Ansoff-Matrix legt das Unternehmen einen ehrgeizigen Kurs in den Bereichen Marktdurchdringung, Entwicklung, Produktinnovation und strategische Diversifizierung fest. Dieser dynamische Ansatz verspricht nicht nur, das genetische Screening und die personalisierte Gesundheitsversorgung zu revolutionieren, sondern positioniert Myriad Genetics auch als Pionier bei der Erschließung des komplexen Potenzials genetischer Erkenntnisse und bietet einen Blick in eine Zukunft, in der fortschrittliche molekulare Diagnostik die Patientenversorgung und das medizinische Verständnis grundlegend verändern kann.

Myriad Genetics, Inc. (MYGN) – Ansoff-Matrix: Marktdurchdringung

Erweitern Sie das Volumen genetischer Tests im Onkologiemarkt

Myriad Genetics meldete für das Geschäftsjahr 2022 einen Gesamtumsatz von 629,4 Millionen US-Dollar, wobei Tests auf erbliche Krebserkrankungen einen erheblichen Anteil ausmachten.

Erhöhen Sie das Engagement Ihrer Vertriebsmitarbeiter

Myriad Genetics unterhält ein Direktvertriebsteam von 187 Vertretern, die sich landesweit an Onkologiezentren wenden.

• Abgedeckt 2.345 Gesundheitsdienstleister
• Etablierte Beziehungen zu 612 Onkologiezentren
• Durchschnittliche Vertriebsinteraktion: 43 Treffen pro Vertreter monatlich

Entwickeln Sie strategische Preismodelle

Die aktuellen Preise für Gentests liegen je nach Komplexität zwischen 349 und 4.500 US-Dollar.

Verbessern Sie Kundenbindungsprogramme

Aktuelle Kundenbindungsrate: 68,3 % für Gentest-Kunden.

• Implementierung personalisierter Nachsorgeprotokolle
• Entwickelte Patientenunterstützungsprogramme
• Erstellung digitaler Plattformen zur Patienteneinbindung

Direct-to-Consumer-Marketing für die Risikovorsorge auf erblich bedingte Krebserkrankungen

Marketinginvestitionen: 42,6 Millionen US-Dollar im Jahr 2022 für Direct-to-Consumer-Kampagnen.

Myriad Genetics, Inc. (MYGN) – Ansoff-Matrix: Marktentwicklung

Erweitern Sie die geografische Reichweite auf internationale Märkte

Myriad Genetics meldete im Geschäftsjahr 2022 einen internationalen Umsatz von 37,5 Millionen US-Dollar, was 16,5 % des Gesamtumsatzes des Unternehmens entspricht. Die europäische Marktdurchdringung stieg im gleichen Zeitraum um 7,2 %.

Erschließen Sie neue Gesundheitssegmente

Die Marktgröße für Fruchtbarkeitstests wird bis 2025 voraussichtlich 1,2 Milliarden US-Dollar erreichen. Das Segment der reproduktiven Gesundheit von Myriad wuchs im Jahr 2022 um 12,4 %.

• Markt für Fruchtbarkeitskliniken: 18,3 % jährliche Wachstumsrate
• Einnahmen aus reproduktiven Gesundheitstests: 45,6 Millionen US-Dollar

Entwickeln Sie Partnerschaften mit Krankenhausnetzwerken

Das aktuelle Partnerschaftsnetzwerk umfasst 237 Krankenhaussysteme. Die Zahl der Forschungskooperationen ist im Jahr 2022 um 15 gestiegen.

Entdecken Sie Schwellenländer

Der Markt für Präzisionsmedizin soll bis 2026 weltweit ein Volumen von 196,2 Milliarden US-Dollar erreichen. Die Investitionen in Schwellenländer beliefen sich 2022 auf insgesamt 12,3 Millionen US-Dollar.

Passen Sie die Angebote für Gentests an

Investitionen in die Einhaltung gesetzlicher Vorschriften in Höhe von 8,7 Millionen US-Dollar im Jahr 2022. Erfolgreiche Erlangung von 14 neuen regionalen Gesundheitszertifizierungen.

• Ausgaben für die Einhaltung gesetzlicher Vorschriften: 8,7 Millionen US-Dollar
• Neue regionale Zertifizierungen: 14

Myriad Genetics, Inc. (MYGN) – Ansoff Matrix: Produktentwicklung

Investieren Sie in fortschrittliche molekulare Diagnosetechnologien für die Krebsvorsorge

Im Jahr 2022 investierte Myriad Genetics 78,3 Millionen US-Dollar in Forschung und Entwicklung für fortschrittliche molekulardiagnostische Technologien. Das Portfolio des Unternehmens zur genetischen Krebsvorsorge erwirtschaftete einen Umsatz von 342,5 Millionen US-Dollar.

Entwickeln Sie neue genetische Panels, die auf seltene genetische Störungen abzielen

Myriad hat im Jahr 2022 sieben neue genetische Panels für seltene Erkrankungen entwickelt, die etwa 150 einzigartige genetische Erkrankungen abdecken.

• Entwicklungskosten für ein Panel für seltene Störungen: 12,6 Millionen US-Dollar
• Geschätzte Marktgröße für Tests seltener genetischer Störungen: 475 Millionen US-Dollar
• Anzahl neu identifizierter genetischer Erkrankungen: 38

Erstellen Sie personalisierte Medizinlösungen unter Einbeziehung genetischer Erkenntnisse

Personalisierte Medizinlösungen generierten für Myriad im Jahr 2022 einen Umsatz von 214,7 Millionen US-Dollar.

Verbessern Sie die Fähigkeiten der Bioinformatik

Myriad investierte im Jahr 2022 56,4 Millionen US-Dollar in die Bioinformatik-Infrastruktur und verarbeitete über 1,2 Millionen Gentests.

• Geschwindigkeit der Computeranalyse: 15.000 genetische Profile pro Tag
• Genauigkeit des maschinellen Lernalgorithmus: 94,7 %
• Datenspeicherkapazität: 3,8 Petabyte

Erweitern Sie Pharmakogenomiktests

Die pharmakogenomischen Tests wurden im Jahr 2022 auf 62 verschiedene Medikamentenkategorien ausgeweitet.

Myriad Genetics, Inc. (MYGN) – Ansoff-Matrix: Diversifikation

Strategische Akquisitionen in komplementären Gentechnologiebereichen

Im Jahr 2019 erwarb Myriad Genetics Assurex Health für 225 Millionen US-Dollar und erweiterte damit sein Portfolio an Präzisionsmedizin. Das Unternehmen meldete für das Geschäftsjahr 2022 einen Gesamtumsatz von 874,2 Millionen US-Dollar.

Digitale Gesundheitsplattformen, die genetische Daten und Patienteneinblicke integrieren

Myriad investierte im Jahr 2022 86,4 Millionen US-Dollar in Forschung und Entwicklung und konzentrierte sich dabei auf die Entwicklung digitaler Plattformen.

• Die MyRisk-Plattform für erblichen Krebs deckt 11 Krebsarten ab
• Die Datenbank für Gentests enthält über 5 Millionen Patientendatensätze

KI-gesteuerte prädiktive Tools zur genetischen Risikobewertung

Das Unternehmen gab im Jahr 2022 13,4 % seines Gesamtumsatzes für Forschung und Entwicklung aus.

Gentestlösungen für aufstrebende medizinische Fachgebiete

Myriad hat seine Gentestdienste auf mehrere medizinische Fachgebiete ausgeweitet und im Jahr 2022 einen Umsatz von 874,2 Millionen US-Dollar generiert.

• Marktanteil onkologischer Gentests: 25 %
• Gentests für reproduktive Gesundheit: Segmentumsatz von 310 Millionen US-Dollar

Bildungs- und Beratungsdienste für die Interpretation genetischer Tests

Myriad hat umfassende genetische Beratungsdienste mit 150 zertifizierten genetischen Beratern entwickelt.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Penetration

Drive GeneSight test volume growth by 20% in the US.

For the third quarter of 2025, GeneSight test volume grew 8% year-over-year. This reflects ongoing improvement from the second quarter of 2025, where GeneSight test volume growth was 5% year-over-year. This growth follows the impact of UnitedHealthcare's discontinuation of coverage effective in the first quarter of 2025.

Increase myRisk hereditary cancer test adoption in underserved US populations.

Hereditary cancer testing volume for the unaffected population increased 11% year-over-year in the third quarter of 2025. In the second quarter of 2025, MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. A recent survey indicated that 37% of women surveyed believe genetic testing can help manage breast health, yet only 14% of respondents reported having undergone genetic testing.

Secure broader payer coverage for Prolaris prostate cancer test in regional plans.

Historically, Prolaris achieved insurance coverage for approximately 50 percent of Prostate cancer patients in the United States, later increasing to cover more than 55 percent of eligible patients. The company continues working with remaining private health insurers to expand access.

Expand telehealth integration to simplify physician ordering and patient access.

Myriad Genetics' full oncology portfolio of germline and tumor genomic tests is expected to be fully integrated with both Flatiron's OncoEMR and Epic cloud-based platforms later this year in 2025. The company offers electronic medical record (EMR) integration to help providers order tests and access results directly within their daily platforms. The partnership with Epic aims to scale tech-enabled commercial capabilities.

Offer bundled testing options to increase average revenue per patient.

In the second quarter of 2025, gross margin benefited from improving average revenue per test trends. However, the first quarter of 2025 saw a year-over-year decrease in the average revenue per hereditary cancer test, largely due to a difference in the change in estimated revenue related to prior periods.

Here's a quick look at recent operational metrics:

The company's strategy involves several key areas to drive penetration:

• Use of EMR solutions for breast cancer risk assessment programs.
• Launching an expanded gene panel for the MyRisk Hereditary Cancer Test later in 2025.
• Entering a collaboration with SOPHiA GENETICS for CDx development services.
• Anticipating the commercial launch of the Precise MRD assay in 2026.
• Planning the launch of the Prolaris test with PATHOMIQ's AI technology in early 2026.

Finance: review the impact of the new $200 million credit facility on Q4 2025 interest expense by Thursday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Development

Accelerate GeneSight launch and reimbursement efforts across major European markets. The Pharmacogenomics revenue segment saw a 20% year-over-year decline in the first quarter of 2025, directly attributed to UnitedHealthcare reducing coverage for GeneSight®.

Establish strategic distribution partnerships in Japan and South Korea for myRisk. Myriad International Offices currently list a presence in Japan as Myriad Genetics G.K..

Target international revenue to reach 15% of total revenue within two years.

Obtain regulatory approvals for Foresight carrier screening in Canada and Australia. The Foresight® Carrier Screen was included in research studies presented at the National Society of Genetic Counselors Annual Conference in November 2025.

Focus sales teams on large, integrated health systems outside the US. The company completed the sale of its international EndoPredict business in August 2024.

Here's the quick math on how the core business performed in 2025, which sets the stage for international focus:

The Hereditary Cancer testing volume in the third quarter of 2025 increased 11% year-over-year, which includes myRisk testing.

The company is working on several product launches that could impact future international market entry:

• AI-enabled Prolaris test targeted for year-end 2025.
• PRECISE MRD targeted for a first-half 2026 launch.
• Commercially launching FirstGene Multiple Prenatal Screen in 2026.

The overall 2025 revenue guidance range was revised to between $807 million and $823 million after the first quarter.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Product Development

You're looking at how Myriad Genetics, Inc. (MYGN) plans to grow by launching new products into existing markets, which is the Product Development quadrant of the Ansoff Matrix. We need to ground this in the numbers they've reported through the third quarter of 2025.

For the commitment to innovation, while the target of $100 million annually in R&D isn't explicitly confirmed in the latest filings, we see the trend. Research and development expense for the full year ended December 31, 2024, increased by $24.7 million compared to the prior year, driven by investments in new products like the MRD test. This investment focus continued into 2025; for instance, Q1 2025 adjusted operating expenses of $140.6 million reflected maintaining investments in key strategic areas, including research and development. This shows the ongoing financial commitment to pipeline advancement.

The next-generation version of myRisk Hereditary Cancer Test saw a significant upgrade as of November 10, 2025. The panel expanded to 63 genes, covering more than 11 cancer types. This update means the test now includes 100% of genes strongly recommended by national oncology guidelines like NCCN and ASCO. This enhancement was achieved by adding 15 newly added guideline-recommended genes and 36 evidence-based intronic variants.

Here's a snapshot of the myRisk expansion:

In prostate cancer diagnostics, Myriad Genetics, Inc. is integrating artificial intelligence (AI) into the Prolaris test. The plan is to launch the first AI-driven prostate cancer clinical test, which integrates PATHOMIQ's AI technology, later in 2025 (with some forward-looking statements suggesting early 2026). This AI platform analyzes digitized H&E whole slide images to predict disease recurrence after initial therapy. The technology is designed to deliver results within 1-2 days after receiving digital patient samples. The collaboration aims to accelerate achieving Simon level 1 evidence for both the Prolaris and the AI component. Prolaris testing revenue itself showed growth of 3% year-over-year in the third quarter of 2025.

Regarding companion diagnostics for oncology drugs, Myriad Genetics, Inc. announced a strategic collaboration on September 23, 2025, with SOPHiA GENETICS to develop an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the US to support clinical trials testing. The initial focus is on the MSK-ACCESS® powered with SOPHiA DDM™ liquid biopsy application. SOPHiA GENETICS supports global deployment through a network of more than 800 connected institutions across over 70 countries.

The development pipeline also includes other areas, though specific financial or launch metrics for a new mental health screening test weren't detailed in the latest reports. However, other product lines show activity, such as the Pharmacogenomics segment revenue declining by 20% in Q1 2025 and (19)% in Q3 2025, signaling a need for new product introductions in that space to offset coverage headwinds, like the UnitedHealthcare reduction. The Prenatal segment, conversely, showed strength, with revenue growing 11% in Q1 2025.

Here are the revenue performance indicators for context on where new products need to drive growth:

• Q3 2025 Hereditary Cancer Revenue: $81.8 million (up 2% year-over-year).
• Q3 2025 Hereditary Cancer Volume: Increased 9% year-over-year.
• Q1 2025 Pharmacogenomics Revenue: $31.0 million (down 20% year-over-year).
• Q2 2025 Hereditary Cancer Volume (Oncology): Grew 10% year-over-year.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Diversification

You're looking at how Myriad Genetics, Inc. (MYGN) can push beyond its core genetic testing base, which is smart given the competitive landscape. Diversification here means moving into new markets or offering new services, which is where the real upside often hides. We are mapping potential moves against a contextual revenue scale of $700 million, aiming for $50 million in new contribution from these efforts.

For context on M&A as a diversification tool, look at past moves. The acquisition of Assurex Health in 2016 was for an upfront cost of $225 million, with potential performance-based milestones reaching $185 million. Assurex generated over $60 million in revenue in Myriad Genetics, Inc.'s fiscal year 2016. More recently, the Counsyl, Inc. acquisition in 2018 was valued at $375 million, which immediately positioned Myriad Genetics, Inc. as a premier Women's Health organization.

Entering the direct-to-consumer (DTC) wellness market with a new, non-diagnostic service is a classic diversification play. Myriad Genetics, Inc. has experience here through the acquisition of Gateway Genomics for $67.5 million, which brought the SneakPeek® Early Gender DNA Test. That test had shown a compound annual growth rate exceeding 20% over the three years prior to the acquisition. This shows a path to scaling a non-diagnostic, consumer-facing offering quickly.

For clinical trial services, Myriad Genetics, Inc. already has deep regulatory experience across the United States, Europe, and Japan. A recent, concrete step is the strategic collaboration announced in September 2025 with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) test. This partnership leverages Myriad Genetics, Inc.'s advanced U.S. laboratory capabilities to support global testing for clinical trials, while SOPHiA GENETICS manages regulatory submissions outside the U.S. This is a tangible move into expanding biopharma services globally.

Developing a new platform for infectious disease monitoring, a new market, is aggressive. While specific infectious disease platform details aren't immediately clear, Myriad Genetics, Inc. is actively developing its Minimal Residual Disease (MRD) testing platform, which is tumor-informed and uses whole-genome sequencing. This platform tracks up to thousands of variants, which is significantly more sensitive than the 50 or fewer variants monitored by most current MRD tests. The Precise MRD assay is planned for a controlled early access launch in 2026. This demonstrates capability in developing entirely new, high-tech platforms for new clinical questions.

To hit the required revenue targets, you need to see where the current business stands against the goal. Full-year 2024 revenue was approximately $838 million, and the reaffirmed 2025 guidance is between $818 million and $828 million. Still, the diversification goal is framed against a $700 million scale. Here's the quick math on how the $50 million target fits into the current business mix, using the 2025 guidance midpoint of $823 million for comparison, even though the prompt specified $700 million as the base for the target.

Achieving the $50 million from new streams means that, relative to the $700 million context, diversification needs to account for approximately 7.14% of that revenue base. The actual revenue base in 2024 was higher at $837.60 million, meaning the actual required percentage of the actual revenue would be closer to 5.97% (50 / 837.60). What this estimate hides is the required investment spend to generate that $50 million, which could impact near-term profitability, as seen by the Q3 2025 adjusted EPS of $0.00.

These diversification avenues require specific execution focus:

• Acquisition: Due diligence on cardiology market size and integration costs.
• DTC Wellness: Scaling digital marketing spend to capture the 4 million annual SneakPeek website visitors.
• Pharma Partnership: Securing 10 companion diagnostic approvals in the U.S. and Japan as a benchmark.
• New Platform: Successfully transitioning the Precise MRD assay from research evaluation to commercial use in 2026.

Finance: draft 13-week cash view by Friday.